Toggle Main Menu Toggle Search

Open Access padlockePrints

Glycation in Parkinson's disease and Alzheimer's disease

Lookup NU author(s): Professor Tiago OuteiroORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2016 International Parkinson and Movement Disorder Society.Glycation is a spontaneous age-dependent posttranslational modification that can impact the structure and function of several proteins. Interestingly, glycation can be detected at the periphery of Lewy bodies in the brain in Parkinson's disease. Moreover, α-synuclein can be glycated, at least under experimental conditions. In Alzheimer's disease, glycation of amyloid β peptide exacerbates its toxicity and contributes to neurodegeneration. Recent studies establish diabetes mellitus as a risk factor for several neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. However, the mechanisms underlying this connection remain unclear. We hypothesize that hyperglycemia might play an important role in the development of these disorders, possibly by also inducing protein glycation and thereby dysfunction, aggregation, and deposition. Here, we explore protein glycation as a common player in Parkinson's and Alzheimer's diseases and propose it may constitute a novel target for the development of strategies for neuroprotective therapeutic interventions.


Publication metadata

Author(s): Vicente Miranda H, El-Agnaf OMA, Outeiro TF

Publication type: Review

Publication status: Published

Journal: Movement Disorders

Year: 2016

Volume: 31

Issue: 6

Pages: 782-790

Print publication date: 01/06/2016

Online publication date: 04/03/2016

Acceptance date: 07/01/2016

ISSN (print): 0885-3185

ISSN (electronic): 1531-8257

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/mds.26566

DOI: 10.1002/mds.26566


Share